Healthcare >> CEO Interviews >> December 2, 1999

Harry Penner Jr. – Neurogen Corporation (nrgn)

HARRY PENNER, JR. is President, Chief Executive Officer, and Vice Chairman of Neurogen Corporation in Branford, CT. Since joining Neurogen in 1993, he has led the company into multiple clinical trials, to dramatic portfolio growth, to important corporate alliances with Pfizer, Schering-Plough, Wyeth-Ayerst, and to a $46 million secondary public offering. Under Mr. Penner's leadership Neurogen has become one of the more broadly based and better financed companies in the biotechnology sector. Mr. Penner serves on the Boards of Directors of Neurogen and Avant Immunotherapeutics, Inc., both of which are public companies. He also serves on the Boards of Directors of PRA International, Inc., a privately held clinical research organization, and Genaissance, Inc., a privately held pharmacogenomics company. Mr. Penner currently serves as Co-Chairman of CURE, Connecticut's Bioscience Cluster, as a member of the Board of Governors of Higher Education in Connecticut, and as a member of the Boards of Directors of the Connecticut Business and Industry Association (CBIA), the Connecticut Technology Council (CTC), and the Biotechnology Industry Organization (BIO). Mr. Penner was previously an Executive Vice President of Novo Nordisk A/S and holds academic degrees from the University of Virginia (BA), Fordham University (JD), and New York University (LLM). Profile
TWST: Give us an overview and history of the Neurogen Corp. What do you

believe will be the significant trends, developments or changes that you

anticipate in your sector of the market over the